BIONTECH SE SPON. ADRS 1
Commented by Nico Popp on September 27th, 2023 | 07:10 CEST
Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics
High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!
Read
Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST
Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets
Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.
Read
Commented by André Will-Laudien on September 11th, 2023 | 07:30 CEST
The next steps towards cannabis THC legalization are underway! Canopy, Tilray and BioNTech are taking the lead, and Cantourage Group is experiencing dynamic growth
Cannabis has been decriminalized in some countries but legalized in only a few states. In the US, cannabis is fully legalized in states such as California but outright banned in others such as Texas. While medical use is slowly catching on, the use as an intoxicant and cultivation for personal use remains controversial. Stronger momentum could be sparked by the US Department of Health and Human Services (HHS). The authorities are open to a downgrading of the degree of danger in the categorization of the US Drug Enforcement Administration (DEA). We are talking about two steps from Schedule I to Schedule III, which no longer puts THC on a par with common drugs such as heroin, ecstasy or LSD but classifies them as substances with comparatively little psychological dependence. That would be a revolutionary step. Which stocks can benefit?
Read
Commented by Stefan Feulner on September 7th, 2023 | 08:00 CEST
Biotech with tailwind - Newron Pharmaceuticals, Defence Therapeutics, BioNTech
There is a lot of activity in the biotechnology sector, even though the broadly diversified Nasdaq Biotech Index reflects this with a performance of only 1% since the beginning of the year. In addition to the increasing number of acquisitions by Big Pharma, promising technologies from second-tier companies are performing extremely well. Furthermore, the surging COVID-19 statistics are instilling hope in vaccine producers as they aim to revive their slumping sales.
Read
Commented by Armin Schulz on September 6th, 2023 | 08:00 CEST
BioNTech, Cardiol Therapeutics, Bayer - Tiger mosquitoes, and rising Corona numbers bring biotech back in focus
Corona infections are already rising, even though autumn has not even begun. Hospitals are already fearing a high burden during the winter. Gerald Gaß, the Chairman of the Board of the German Hospital Federation, advised high-risk patients, their close contacts and healthcare workers to keep their flu and COVID-19 vaccinations up to date. Due to constant stress triggered by crises and workload-related pressures, the number of heart patients have also increased in recent years. At the end of August, entire neighborhoods and streets in Paris were closed off to spray insecticides against tiger mosquitoes, which spread diseases like dengue and Zika viruses, among others. This is reason enough for us to examine three companies fighting these threats.
Read
Commented by Nico Popp on August 30th, 2023 | 07:00 CEST
Course Rockets of Yesterday - and Tomorrow: Innocan Pharma, BioNTech, Cardiol Therapeutics
According to the information service IQVIA, dietary supplements generate almost EUR 3 billion in sales in Germany - and the trend is rising. More and more people are paying attention to their health and are not satisfied when the doctor says, "You are healthy." In fact, there is still a lot of upside potential for healthy people, too - for example, when it comes to reducing stress, improving sleep or strengthening the body's own defenses. Today, we highlight three stocks that could benefit from increased health awareness.
Read
Commented by André Will-Laudien on August 23rd, 2023 | 07:00 CEST
Climate change or just a heat wave? - BioNTech, Cardiol Therapeutics, and Redcare Pharmacy deliver!
Whether this consistently warm summer already documents a pronounced climate change is questionable. The older ones among us remember that there were already very hot summers before and that even in the last 30 years, there was rarely snow at Christmas. However, human life is simply too short for significant conclusions. Therefore, long-term weather records have to be consulted. There will probably be a slight increase in average temperatures, but we will get little information about when the next ice age will hit us. For many politicians, the current weather trends fit perfectly into the chain of arguments in favor of radical legislative proposals. Perhaps, however, the caprices of the weather are only the offshoots of the approaching El Nino. The stock market also follows changing trends; after the flood, an ebb could now be imminent. Selection remains key!
Read
Commented by Armin Schulz on August 16th, 2023 | 05:40 CEST
BioNTech, Defence Therapeutics, Bayer - Who will have trend-setting news first?
Pharmaceutical and biotech stocks are among the most volatile sectors in the financial markets. Single news stories about new developments or product announcements can not only cause short-term price swings but also have long-term implications, increasing both risk and opportunity for investors. If a breakthrough drug is developed, old preparations can become obsolete - this is good for the innovative company but detrimental to established market participants. As an investor, it is advisable to select specific companies and anticipate directional news through some research.
Read
Commented by Stefan Feulner on August 2nd, 2023 | 09:15 CEST
Well positioned for the future - BioNTech, Defence Therapeutics, Sanofi
There is currently a lot of movement in the capital-intensive biotech sector. After second-tier companies, in particular, were hit hard by the effects of tighter monetary policy last year and at times traded below their cash levels, many are now considered hot takeover candidates thanks to their innovative technologies. The well-heeled pharma giants must act to avoid missing out on future blockbusters.
Read
Commented by Armin Schulz on July 27th, 2023 | 07:15 CEST
BioNTech, Defiance Silver, Vonovia - Waiting for the turnaround
The stock market is not a one-way street, so it happens time and again that companies that initially performed well run into problems, leading to falling prices. After an extended period of underperformance, bargain hunters often step in, seeking the right entry point to profit from a potential turnaround. One announcement can turn the tide and influence the price of a stock. We have selected three candidates where a turnaround could be imminent, provided an appropriate news catalyst exists.
Read